Published in Clin Cancer Res on June 09, 2009
GW786034 in Treating Patients With Advanced Solid Tumors | NCT00060151
Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol (2010) 3.75
Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov (2014) 2.79
Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nat Rev Clin Oncol (2012) 2.01
An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol (2009) 1.80
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol (2014) 1.67
Plasma cytokine and angiogenic factor profiling identifies markers associated with tumor shrinkage in early-stage non-small cell lung cancer patients treated with pazopanib. Cancer Res (2010) 1.58
Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther (2010) 1.23
A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium. Oncologist (2010) 1.22
(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist (2010) 1.20
Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol (2013) 1.18
Design considerations for dose-expansion cohorts in phase I trials. J Clin Oncol (2013) 1.15
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J Clin Oncol (2012) 1.09
Effect of pazopanib on tumor microenvironment and liposome delivery. Mol Cancer Ther (2010) 1.09
A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. Cell Death Dis (2015) 1.02
Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. Oncologist (2013) 0.99
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours. Br J Cancer (2013) 0.97
Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors. Oncologist (2011) 0.96
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist (2010) 0.95
Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer. Oncotarget (2015) 0.94
Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. Br J Cancer (2014) 0.92
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs (2011) 0.92
Targeted therapy in renal cancer. Ther Adv Med Oncol (2009) 0.92
New molecular targeted therapies for advanced non-small-cell lung cancer. J Thorac Dis (2011) 0.91
The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer. BMC Cancer (2011) 0.90
A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat (2012) 0.88
Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica (2014) 0.87
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2013) 0.87
Angiogenesis in cancer: Anti-VEGF escape mechanisms. Transl Lung Cancer Res (2012) 0.87
Computational repositioning and preclinical validation of pentamidine for renal cell cancer. Mol Cancer Ther (2014) 0.87
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. Onco Targets Ther (2010) 0.87
Antiangiogenic therapies in early-stage breast cancer. Clin Breast Cancer (2010) 0.86
Dysphonia induced by anti-angiogenic compounds. Invest New Drugs (2013) 0.86
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res (2015) 0.85
Pazopanib in sarcomas: expanding the PALETTE. Curr Opin Oncol (2013) 0.85
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models. PLoS One (2011) 0.84
Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs (2011) 0.84
Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. Anticancer Drugs (2013) 0.83
Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer. J Cancer Res Clin Oncol (2013) 0.83
Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib. Onco Targets Ther (2013) 0.82
Tyrosine kinase inhibitors in the treatment of advanced renal cell carcinoma: focus on pazopanib. Clin Med Insights Oncol (2011) 0.82
Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. Br J Cancer (2012) 0.82
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy. Oncotarget (2014) 0.81
Pazopanib for the treatment of soft-tissue sarcoma. Clin Pharmacol (2012) 0.81
Concise drug review: pazopanib and axitinib. Oncologist (2012) 0.81
Axitinib plasma pharmacokinetics and ethnic differences. Invest New Drugs (2015) 0.80
Pazopanib exposure decreases as a result of an ifosfamide-dependent drug-drug interaction: results of a phase I study. Br J Cancer (2013) 0.80
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma. Cancer Manag Res (2011) 0.78
Pazopanib: approval for soft-tissue sarcoma. J Adv Pract Oncol (2013) 0.78
Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials. Invest New Drugs (2010) 0.78
Targeting angiogenesis in advanced cervical cancer. Ther Adv Med Oncol (2014) 0.78
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer. Expert Opin Pharmacother (2013) 0.78
Developmental therapeutics for inflammatory breast cancer: Biology and translational directions. Oncotarget (2016) 0.77
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther (2016) 0.77
Pharmacotherapy options in advanced renal cell carcinoma: what role for pazopanib? Clin Med Insights Oncol (2011) 0.77
Establishment of a novel clear cell sarcoma cell line (Hewga-CCS), and investigation of the antitumor effects of pazopanib on Hewga-CCS. BMC Cancer (2014) 0.77
New antiangiogenics in non-small cell lung cancer treatment: Vargatef™ (BIBF 1120) and beyond. Ther Clin Risk Manag (2011) 0.77
Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma. CPT Pharmacometrics Syst Pharmacol (2015) 0.77
Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection. J Anal Methods Chem (2015) 0.77
A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs (2014) 0.76
Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insights Oncol (2010) 0.76
Overview of fundamental study of pazopanib in cancer. Thorac Cancer (2014) 0.76
Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer. Oncotarget (2016) 0.76
Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours. Br J Cancer (2015) 0.76
Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep (2015) 0.76
Prevention of Pazopanib-Induced Prolonged Cardiac Repolarization and Proarrhythmic Effects. Arq Bras Cardiol (2014) 0.75
Pazopanib in the management of advanced soft tissue sarcomas. Ther Clin Risk Manag (2016) 0.75
Pazopanib for Non-small Cell Lung Cancer: The First Case Report in Korea. Cancer Res Treat (2015) 0.75
Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis. Oncotarget (2016) 0.75
An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers Ther (2015) 0.75
Activation of ERK1/2 Causes Pazopanib Resistance via Downregulation of DUSP6 in Synovial Sarcoma Cells. Sci Rep (2017) 0.75
Neoadjuvant Therapy in Differentiated Thyroid Cancer. Int J Surg Oncol (2016) 0.75
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma. Biologics (2010) 0.75
Pazopanib and anti-VEGF therapy. Open Access J Urol (2010) 0.75
A Phase I, Dose-Escalation Trial of Pazopanib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A UNICANCER Study. Oncol Ther (2016) 0.75
Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. Cancer Chemother Pharmacol (2017) 0.75
Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient. Front Pharmacol (2017) 0.75
Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. BMC Cancer (2017) 0.75
Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. Invest New Drugs (2015) 0.75
Targeting FGFR in Squamous Cell Carcinoma of the Lung. Target Oncol (2017) 0.75
Pazopanib: a Review in Advanced Renal Cell Carcinoma. Target Oncol (2017) 0.75
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med (2006) 34.52
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Review of internal hernias: radiographic and clinical findings. AJR Am J Roentgenol (2006) 5.32
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol (2005) 2.77
Reproducibility of dynamic contrast-enhanced MR imaging. Part I. Perfusion characteristics in the female pelvis by using multiple computer-aided diagnosis perfusion analysis solutions. Radiology (2012) 2.51
Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol (2012) 1.95
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2008) 1.93
Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res (2004) 1.91
Renal stone assessment with dual-energy multidetector CT and advanced postprocessing techniques: improved characterization of renal stone composition--pilot study. Radiology (2009) 1.90
Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res (2007) 1.88
Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol (2008) 1.79
Endovascular treatment of visceral artery aneurysms. J Endovasc Ther (2002) 1.75
Gadoxetate disodium-enhanced MRI of the liver: part 1, protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol (2010) 1.70
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol (2006) 1.68
Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2. J Clin Oncol (2008) 1.57
Phase I trial of fludarabine, bortezomib and rituximab for relapsed and refractory indolent and mantle cell non-Hodgkin lymphoma. Br J Haematol (2009) 1.56
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. Clin Chem (2010) 1.53
Confirmation of gene expression-based prediction of survival in non-small cell lung cancer. Clin Cancer Res (2008) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Phase I trial of pelvic radiation, weekly cisplatin, and 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) for locally advanced cervical cancer. Clin Cancer Res (2010) 1.45
Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res (2005) 1.44
Short- and midterm reproducibility of apparent diffusion coefficient measurements at 3.0-T diffusion-weighted imaging of the abdomen. Radiology (2008) 1.41
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. Cancer Res (2007) 1.41
Challenges in screening for hepatocellular carcinoma in the glycogen storage disease type 1a population. Intern Med (2012) 1.38
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol (2010) 1.37
A review of MR physics: 3T versus 1.5T. Magn Reson Imaging Clin N Am (2007) 1.37
Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol (2008) 1.37
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid (2009) 1.35
Gadoxetate disodium-enhanced MRI of the liver: part 2, protocol optimization and lesion appearance in the cirrhotic liver. AJR Am J Roentgenol (2010) 1.33
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol (2009) 1.27
Toxicity of sunitinib plus bevacizumab in renal cell carcinoma. J Clin Oncol (2010) 1.23
Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists? J Clin Oncol (2006) 1.21
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid (2013) 1.19
A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin Cancer Res (2009) 1.18
Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol (2010) 1.17
A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers. Clin Cancer Res (2009) 1.10
The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res (2013) 1.10
Phase II study of bryostatin 1 and vincristine for aggressive non-Hodgkin lymphoma relapsing after an autologous stem cell transplant. Am J Hematol (2009) 1.09
Hepatobiliary MR imaging with gadolinium-based contrast agents. J Magn Reson Imaging (2012) 1.08
Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res (2011) 1.08
Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer. Lung Cancer (2006) 1.06
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res (2008) 1.04
Consensus report of the 4th International Forum for Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid Magnetic Resonance Imaging. Korean J Radiol (2011) 1.04
Hepatocellular carcinoma in a North American population: does hepatobiliary MR imaging with Gd-EOB-DTPA improve sensitivity and confidence for diagnosis? J Magn Reson Imaging (2012) 1.03
Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. Clin Cancer Res (2010) 1.03
Low-flow vascular malformations: MR-guided percutaneous sclerotherapy in qualitative and quantitative assessment of therapy and outcome. Radiology (2004) 1.02
Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol (2013) 1.02
RET mutation and expression in small-cell lung cancer. J Thorac Oncol (2014) 1.01
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res (2013) 1.00
Comparison of power between randomized discontinuation design and upfront randomization design on progression-free survival. J Clin Oncol (2009) 1.00
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist (2013) 0.98
Time-resolved MR angiography as a useful sequence for assessment of ovarian vein reflux. AJR Am J Roentgenol (2009) 0.98
Calcified vascular plaque specimens: assessment with cardiac dual-energy multidetector CT in anthropomorphically moving heart phantom. Radiology (2008) 0.97
Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. Oncologist (2010) 0.95
The association and nuclear translocation of the PIAS3-STAT3 complex is ligand and time dependent. Mol Cancer Res (2009) 0.95
Multislice helical CT of the pancreas and spleen. Eur J Radiol (2003) 0.95
Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies. J Clin Oncol (2007) 0.94
Focal cystic high-attenuation lesions: characterization in renal phantom by using photon-counting spectral CT--improved differentiation of lesion composition. Radiology (2010) 0.94
Therapeutic challenges of AIDS-related non-Hodgkin's lymphoma in the United States and East Africa. J Natl Cancer Inst (2002) 0.94
Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. Clin Cancer Res (2007) 0.94
Identification of a class of novel tubulin inhibitors. J Med Chem (2012) 0.94
Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer (2009) 0.94
MRI of the pelvis in women: 3D versus 2D T2-weighted technique. AJR Am J Roentgenol (2010) 0.94
Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol (2011) 0.93
Central veins of the chest: evaluation with time-resolved MR angiography. Radiology (2008) 0.93
N/2 ghosting artifacts: elimination at 3.0-T MR cholangiography with SPACE pulse sequence. Radiology (2008) 0.93
Coronary stent patency: dual-energy multidetector CT assessment in a pilot study with anthropomorphic phantom. Radiology (2008) 0.93
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. Invest New Drugs (2011) 0.92
Differentiating a chronic hyperplastic mass from pancreatic cancer: a challenge remaining in multidetector CT of the pancreas. Eur Radiol (2003) 0.91
Improved liver lesion conspicuity by increasing the flip angle during hepatocyte phase MR imaging. Eur Radiol (2010) 0.91
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs (2012) 0.91
Chemotherapy in patients > or = 80 with advanced non-small cell lung cancer: combined results from SWOG 0027 and LUN 6. J Thorac Oncol (2007) 0.90
Phase I trial of pomalidomide given for patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol (2012) 0.90
Synthesis and anticancer mechanism investigation of dual Hsp27 and tubulin inhibitors. J Med Chem (2013) 0.90
Improvement in B1-inhomogeneity artifacts in the abdomen at 3T MR imaging using a radiofrequency cushion. J Magn Reson Imaging (2008) 0.90
A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck. Cancer Chemother Pharmacol (2004) 0.89
Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol (2013) 0.89
Bevacizumab maintenance in patients with advanced non-small-cell lung cancer, clinical patterns, and outcomes in the Eastern Cooperative Oncology Group 4599 Study: results of an exploratory analysis. J Thorac Oncol (2012) 0.89
A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol (2007) 0.89
Multi-detector row CT of the small bowel: peak enhancement temporal window--initial experience. Radiology (2007) 0.89
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer. Invest New Drugs (2014) 0.89
Liver MRI in the hepatocyte phase with gadolinium-EOB-DTPA: does increasing the flip angle improve conspicuity and detection rate of hypointense lesions? J Magn Reson Imaging (2011) 0.89
A randomized, double-blind, placebo-controlled study to evaluate the effect of repeated oral doses of pazopanib on cardiac conduction in patients with solid tumors. Cancer Chemother Pharmacol (2013) 0.89
Phase I study of pazopanib in combination with paclitaxel and carboplatin given every 21 days in patients with advanced solid tumors. Mol Cancer Ther (2012) 0.88
Abdominal magnetic resonance imaging at 3.0 T what is the ultimate gain in signal-to-noise ratio? Acad Radiol (2006) 0.88
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer Chemother Pharmacol (2010) 0.88
Combined SCLC clinical and pathologic characteristics. Clin Lung Cancer (2012) 0.88
Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2013) 0.87